The deluge of bad news reported by Vical just won’t let up. The biotech conformed today it has abandoned its lead genital herpes vaccine program after a negative phase 2 trial, following in the footsteps of earlier cancer and cytomegalovirus candidates.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,